Guava Technologies has announced the appointment of David Ferrick to the position of vice president, biology and clinical applications
New VP biology and clinical applications Guava Technologies has announced the appointment of David Ferrick to the position of vice president, biology and clinical applications.
Ferrick was previously chief executive officer and director of Sagres Discovery, a California-based onco-genome research and cancer drug discovery company that he co-founded in 1999.
"David Ferrick has a consistently outstanding track record of translating scientific ideas and research breakthroughs into commercial opportunities and innovative products," said Rajen Dalal, president and CEO of Guava Technologies.
"His expertise will help our company serve the worldwide community of cell biologists and medical researchers as he leads expansion of Guava's versatile cell-based analysis systems into clinical testing and novel cell-based assays, and partners with leading laboratories and companies.
"I am delighted to have David join Guava's leadership team".
Prior to co-founding Sagres Discovery, Ferrick served as director, molecular and cellular biology from 1997 to 1999 at Rigel Pharmaceuticals in South San Francisco.
He has also had a distinguished academic career focused in the areas of immunology, inflammation and infectious diseases, and was responsible for designing a number of biochemical and biological assays, as well as genomic tools related to protein identification and immunology.
Dr Ferrick was associate professor, Department of Pathology, Microbiology and Immunology, at the University of California, Davis where his was the first lab to publish a method for detecting intracellular production of cytokines using flow cytometry.
He also established the world's first clinical immunology laboratory for marine mammals.
Previously he worked at the Ontario Cancer Research Center with Tak Mak, and conducted research in malaria and infectious diseases at the Walter Reed Army Institute.
